Peer Review History

Original SubmissionFebruary 26, 2021
Decision Letter - Francois Blachier, Editor

PONE-D-21-06559

The human microbiome and COVID-19: A systematic review

PLOS ONE

Dear Dr. Yamamoto,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses all the points raised during the review process by the 3 reviewers.

Particularly, you will see that all reviewers although finding your work of great interest, asked for additional information regarding notably the precise methodology used for structuring the review, the criteria of severity used in the different studies cited, the control of possible bias and inherent limitation regarding the individual studies referenced. 

Please submit your revised manuscript by May 27 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Francois Blachier, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

  1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3, Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Even if it seems interesting to study the potential association between the dysbiosis and the immune response to the SARS_CoV_2, it should have been done with more well defined methodology. What is the real scope of the review ? Association between severity of the disease and ? With which criterias ? How the biais are controlled in the studies selected ?

The methodology of the studies retained are not well enough detailed. So it is impossible for the reader to assess the validity of the association described.

Reviewer #2: Yamamoto et al. conducted a systematic literature review on the association between the

microbiome and COVID-19 in humans. They shown that human fecal and respiratory tract microbiome changed in COVID-19 patients with opportunistic pathogen abundance. The quality of the process to conducted this study is excellent. Please find my comments.

- The conclusion need to be more shorter with a highlight in terms of Microbiome dysbiosis.

- Do you think that there is non supplementation with probiotics or prebiotics or fermented food in patients ?

- Can you added your recommendations or can you speculate if patients can be supplemented with probiotics ?

- Can microbiota dysbiosis be uses as a signature of COVID-19 severity (as a biomarker)?

- The aspect of microbiota or microbiome modulation in patients can be discussed.

- The prevention or therapeutic aspects : can you comments please?

- One of the limitation may be the lack of metabolomics studies, can you comments on this point.

Reviewer #3: In this systematic review, the authors collected evidence on alterations in the gut, upper and lower respiratory microbiota in Covid-19 infection.

The study is well conducted and written, offering a good perspective on the work in literature.

The evidence collected is unfortunately of low grade. All the studies collected had an observational design, 14/16 are conducted in China and consider only hospitalized patients. For these reasons, many confounding factors may have altered the results. Moreover, different types of samples and different methods of analysis are used.

Major revision

- Clarify whether unpublished studies were reviewed by a third-party researcher not involved in the study.

Minor revision

- The design and characteristics of the included studies are well described in Table 1. However, they could be reported more clearly in the text.

- In the "Selection criteria and search strategy" paragraph, words used for the research could be placed in quotation marks rather than in parentheses.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Marvin Edeas, MD, PhD

Professor of Medicine

Université de Paris, INSERM U1016

Institut Cochin

Department Endocrinology, Metabolism

and Diabetes

Faculté de médecine Cochin-Port Royal

24 rue du Faubourg St Jacques,

75014 Paris-France

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachments
Attachment
Submitted filename: Rev. Microbiota and Covid-19.docx
Revision 1

Reviewer #1: Even if it seems interesting to study the potential association between the dysbiosis and the immune response to the SARS_CoV_2, it should have been done with more well defined methodology. What is the real scope of the review ? Association between severity of the disease and ? With which criterias ? How the biais are controlled in the studies selected ?

The methodology of the studies retained are not well enough detailed. So it is impossible for the reader to assess the validity of the association described.

Response: Thank you for your comment. All of your suggestions have been incorporated into our revised manuscript. The scope of review has been provided in the Introduction section (Page 4, line 72−74)” Moreover, in this review, the relationship between the human microbiome and COVID-19 severity has been investigated”. The severity criteria have been added to the Result (Page 8,9 line 189-190) and Supplementary sections. We assessed the risk of bias in each study (Supplementary Table 1).

Reviewer #2: Yamamoto et al. conducted a systematic literature review on the association between the microbiome and COVID-19 in humans. They shown that human fecal and respiratory tract microbiome changed in COVID-19 patients with opportunistic pathogen abundance. The quality of the process to conducted this study is excellent. Please find my comments.

- The conclusion need to be more shorter with a highlight in terms of Microbiome dysbiosis.

Response: Thank you for your comment. The conclusion section has been shortened as suggested. Page 15. line 354−355. “In conclusion, limited evidence implies that COVID-19 patients had altered gut and respiratory tract microbiomes along with an increased abundance of OPs.”

- Do you think that there is non supplementation with probiotics or prebiotics or fermented food in patients ?

- Can you added your recommendations or can you speculate if patients can be supplemented with probiotics ?

- Can microbiota dysbiosis be uses as a signature of COVID-19 severity (as a biomarker)?

- The aspect of microbiota or microbiome modulation in patients can be discussed.

- The prevention or therapeutic aspects : can you comments please?

Response: Thank you for your comment. All of your suggestions have been incorporated into our revised manuscript. Information on probiotics, prebiotics, or fermented food and microbiome modulation and clinical use of microbiome have been provided in the discussion section. Page 14, line 329-332. “If the gut microbiota profile for each disease severity becomes clear in the future. The microbiome may become a prognostic marker for disease progression. Furthermore, in that case, early control of the gut microbiota (e.g., by symbiotics, probiotics, fermented food, and fecal transplant) would be effective in the aspect of prevention or therapeutics..”

- One of the limitation may be the lack of metabolomics studies, can you comments on this point.

Response: Thank you. A relevant text has been added to the limitation paragraph of the Discussion section. Page 15, line 347−352. “Fifth, our review lacked metabolomics studies. Although it is unclear whether changes in the bacterial flora are a cause or consequence, changes in secondary metabolites secreted by bacteria may lead to changes in the gut environment, which may be related to the pathogenesis of the disease by leading to some inflammatory stimuli. Further elucidation of the correlation between metabolomics and human microbiome due to SARS-CoV-2 infection is expected..”

Reviewer #3: In this systematic review, the authors collected evidence on alterations in the gut, upper and lower respiratory microbiota in Covid-19 infection.

The study is well conducted and written, offering a good perspective on the work in literature.

The evidence collected is unfortunately of low grade. All the studies collected had an observational design, 14/16 are conducted in China and consider only hospitalized patients. For these reasons, many confounding factors may have altered the results. Moreover, different types of samples and different methods of analysis are used.

Major revision

- Clarify whether unpublished studies were reviewed by a third-party researcher not involved in the study.

Response: Thank you for your suggestions. The unpublished studies (Yu et al. 2020, Budding AE, et al. 2020, Ai JW, et al.2020) reported were not peer-reviewed by a third-party researcher. This information has been provided in the revised manuscript. Page 5, line 114.

Minor revision

- The design and characteristics of the included studies are well described in Table 1. However, they could be reported more clearly in the text.

Response: Thank you for your comment. Revisions describing the included studies have been made to the revised manuscript (Page 7, line 143−144, 145, 148−149, 157,160-161. Page 8, line 174-175; Page 9, line 196, 212; Page 11, line 244-245).

- In the "Selection criteria and search strategy" paragraph, words used for the research could be placed in quotation marks rather than in parentheses

Response: Thank you for your suggestion. Each searched terms were placed in quotation marks as suggested, and some round brackets that are needed as an operator for the search condition were retained.

Attachments
Attachment
Submitted filename: Response_to_reviewers_MS_SY_MS.docx
Decision Letter - Francois Blachier, Editor

The human microbiome and COVID-19: A systematic review

PONE-D-21-06559R1

Dear Dr. Mizutani,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Francois Blachier, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors are very clear with the fact that the article is exploratory. It is still quite difficult to extrapolate the observations reported in the review and more, it is not simple to imagine any clinical implications of these observations. Nevertheless, it is interesting to observe that, like for other diseases, dysbiosis is associated with covid19. All the results of the articles included in the review are well reported.

Reviewer #2: Thanks for all your comments and the clarifications. The paper is excellent and will provide a strong contribution to this field.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Marvin EDEAS

Formally Accepted
Acceptance Letter - Francois Blachier, Editor

PONE-D-21-06559R1

The human microbiome and COVID-19: A systematic review

Dear Dr. Mizutani:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Francois Blachier

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .